Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 32Cisplatin 23Cetuximab 14Carboplatin 13Magnetic Resonance Spectroscopy 12Specimen Handling 10Radiotherapy, Intensity-Modulated 10Paclitaxel 9Nivolumab 9Docetaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Radiotherapy 5Biopsy 5dostarlimab 4atezolizumab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Taxes 3Radiation 3Fulvestrant 3Fluorouracil 3budigalimab 2amivantamab 2abemaciclib 2Radiotherapy, Image-Guided 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × berzosertib × 30 days × Clear all
NCT02567422 2026-06-02

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
43 enrolled 16 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡